Cargando…

The Effect of Ranibizumab on Normal Neurosensory Retina in the Eyes of Patients with Exudative Age Related Macular Degeneration

BACKGROUND: Anti-vascular endothelial growth factors have become the mainstay treatment for neovascular age related macular degeneration. Prolonged suppression of vascular endothelial growth factor raises concerns as it may result in harmful effects on retina. OBJECTIVE: The purpose of this retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makri, Olga E., Vavvas, Demetrios, Plotas, Panagiotis, Pallikari, Athina, Georgakopoulos, Constantine D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Open 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759102/ https://www.ncbi.nlm.nih.gov/pubmed/29399233 http://dx.doi.org/10.2174/1874364101711010368

Ejemplares similares

Intravitreal aflibercept for choroidal neovascularization secondary to angioid streaks in a non-responder to intravitreal ranibizumab
por: Makri, Olga E, et al.
Publicado: (2018)

Effect of intravitreal injection of aflibercept on blood coagulation parameters in patients with age-related macular degeneration
por: Georgakopoulos, Constantinos D., et al.
Publicado: (2020)

Late-Onset Bilateral Choroidal Metastases from Clear Cell Renal Cell Carcinoma
por: Georgakopoulos, Constantinos D., et al.
Publicado: (2020)

The Acute Effects of Electronic Cigarette Vaping and Tobacco Cigarette Smoking on Choroidal Thickness in Young, Healthy, Habitual, Dual Smokers
por: Makri, Olga E., et al.
Publicado: (2020)

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration
por: Barthelmes, Daniel, et al.
Publicado: (2016)

Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration
por: Pan, Hai-Tao, et al.
Publicado: (2020)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
por: Narayan, Daniel Sanju, et al.
Publicado: (2015)

Cystoid macular edema associated with preservative-free latanoprost after uncomplicated cataract surgery: case report and review of the literature
por: Makri, Olga E., et al.
Publicado: (2017)

The effect of ranibizumab versus photodynamic therapy on DNA damage in patients with exudative macular degeneration
por: Mozaffarieh, M, et al.
Publicado: (2009)

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
por: Canan, Handan, et al.
Publicado: (2014)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
por: Koike, Naoko, et al.
Publicado: (2019)

Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study
por: Schauwvlieghe, A. M. E., et al.
Publicado: (2016)

The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
por: Suzuki, Hiroyuki, et al.
Publicado: (2017)

Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size
por: Nishimura, Yoshihiro, et al.
Publicado: (2012)

One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration
por: Nakamura, Tomoko, et al.
Publicado: (2012)

Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes
por: Figurska, Małgorzata, et al.
Publicado: (2011)

Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration
por: Panos, Georgios D, et al.
Publicado: (2013)

AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE–RELATED MACULAR DEGENERATION: The ARI2 Study
por: Blanco-Garavito, Rocio, et al.
Publicado: (2018)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

A UPLC–MS Method for the Determination of Ofloxacin Concentrations in Aqueous Humor
por: Plotas, Panagiotis, et al.
Publicado: (2014)

Ganglion Cell Complex Evaluation in Exudative Age-Related Macular Degeneration after Repeated Intravitreal Injections of Ranibizumab
por: Perdicchi, Andrea, et al.
Publicado: (2015)

Role of ranibizumab in management of macular degeneration
por: Singh, Rishi P, et al.
Publicado: (2007)

Impact of Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration on Eyes With Intermediate Age-Related Macular Degeneration
por: Chan, Clement K., et al.
Publicado: (2023)

Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients
por: Yamamoto, Akiko, et al.
Publicado: (2013)

Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration
por: Hariprasad, Seenu M., et al.
Publicado: (2012)

Dexamethasone implant for immunogammopathy maculopathy associated with IgA multiple myeloma
por: Georgakopoulos, Constantine D., et al.
Publicado: (2019)

Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
por: Blazaki, Styliani, et al.
Publicado: (2023)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity
por: Monés, Jordi, et al.
Publicado: (2012)

Optical Coherence Tomography-Based Deep-Learning Models for Classifying Normal and Age-Related Macular Degeneration and Exudative and Non-Exudative Age-Related Macular Degeneration Changes
por: Motozawa, Naohiro, et al.
Publicado: (2019)

Neuroprotection for Age-Related Macular Degeneration
por: Lin, Jonathan B., et al.
Publicado: (2022)

Effect of topical isopropyl unoprostone on macular atrophy progression in eyes with exudative age-related macular degeneration
por: Shiragami, Chieko, et al.
Publicado: (2017)

Advances in Age-related Macular Degeneration Understanding and Therapy
por: Miller, Joan W, et al.
Publicado: (2017)

The Injection Practice Patterns of Retina Specialists in Managing Exudative Age-Related Macular Degeneration: A Retrospective Study
por: Karimaghaei, Cina, et al.
Publicado: (2023)

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
por: Karagiannis, Dimitrios A, et al.
Publicado: (2009)

Lucentis(®) using Visudyne(®) study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration
por: Chen, Eric, et al.
Publicado: (2010)

Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)
por: Wykoff, Charles C, et al.
Publicado: (2014)

Treatment of age-related macular degeneration: focus on ranibizumab
por: Spitzer, Martin S, et al.
Publicado: (2008)

Effects of Vitreomacular Traction on Ranibizumab Treatment Response in Eyes with Neovascular Age-related Macular Degeneration
por: Lee, Kang Hoon, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_llaabnsq5e09vtmb1r6jtuok02